A crossover study to evaluate the efficacy and safety of preprandial human insulin inhalation powder (HIIP) compared to once-daily NPH [insulin suspension isophane] in insulin-naive patients with type 2 diabetes mellitus on oral agents

Next Previous
Trial Profile

A crossover study to evaluate the efficacy and safety of preprandial human insulin inhalation powder (HIIP) compared to once-daily NPH [insulin suspension isophane] in insulin-naive patients with type 2 diabetes mellitus on oral agents

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Insulin; Insulin suspension isophane
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Eli Lilly

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Jul 2007 Status changed from initiated
    • 25 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top